The cells co-expressing CD44/CD24 were scarce at stages I and II (less than 0.34%) but were enriched in the NPC samples at advanced stages, especially at stages III and IV (2.2–19.9%) (Figure 2B). Here, CD24 is linked to nasopharyngeal carcinoma.